Chakraborty et al. [26] postulate that selective inhibitors of IP6K1 have therapeutic potential for treating type-2 diabetes associated with obesity and insulin resistance, whereas Bhandari [91] considers lower fasting serum insulin in IP6K1 knockout mice to be evidence of a mandatory activity of IP6K1 in enhancing insulin release from pancreas β cells. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.